When I met Bruce in a consultation, he spoke loudly and rapidly, and I had difficulty interrupting him. It wasn't hard to figure out that he had been living with an unrecognized and untreated psychiatric illness that had driven him to the edge of ruin -- bipolar disorder, also known as manic depression.
Like most diseases, bipolar disorder comes in different shapes and sizes and can be difficult to diagnose. Few people or physicians would miss classic bipolar disorder, with its cyclic episodes of severe depression and full-blown mania. After all, there is nothing subtle about mania, grandiose and often psychotic thinking, elated mood, superhuman energy and libido and reckless judgment.
But a milder form of mania, called hypomania, is not obvious at all, especially in someone like Bruce who happens to be temperamentally dramatic and lively. That is because hypomanic people feel very happy, have lots of energy, need little sleep and are generally fun to be with. And they certainly do not run to doctors complaining of happiness.
So it is easy to see how hypomania could masquerade as cheerful character. In the same way, dysthymia, hypomania's dark twin, has often been confused with gloomy temperament, when in fact it is a treatable form of low-grade depression.
Unlike depression, though, hypomania is intrinsically pleasurable. It is a better-than-well state that often confers a heightened sense of creativity and power.
So what is the down side to hypomania? Well, it can subtly and sometimes powerfully impair a person's judgment. After all, exuberance and supreme confidence can blind someone to the potential consequences of decisions.
Despite obvious financial constraints, Bruce went through long periods of extravagant spending with an inflated sense of his own power and ability. The results proved catastrophic. Not only that, but hypomania is very often an unstable state that cycles into periods of depression, which are sometimes very severe. When that happens, as in Bruce's case, it is called bipolar type 2 disorder.
Bipolar disorder is a potentially fatal illness, because 10 to 20 percent of patients commit suicide, the National Institute of Mental Health says.
According to a survey sponsored by the institute, the prevalence of bipolar disorder is 1.1 percent. That estimate covers just people with the classic form of the disorder.
A more recent survey by Dr. Robert M. Hirschfeld, published in The Journal of Clinical Psychiatry in 2003, found significant bipolar symptoms in 3.7 percent of the United States population. About 20 percent of people identified as bipolar in the survey had been given correct diagnoses, and most had not received effective treatment. The study also found a much higher rate of bipolar disorder, 9.3 percent, among patients 18 to 24 years of age.
The very different rates reported in these two surveys reflect different questions, definitions and methods to diagnose bipolar disorder. If a survey includes the milder types, as the above study did, the prevalence will be much higher.
In fact, the whole spectrum of bipolar disorder is very broad. Some people learn for the first time that they have bipolar disorder when they are treated for depression. That's because antidepressants can precipitate mania in 5 to 10 percent of people with no histories of mania.
Depression is associated with decreased activity of important neurotransmitters like serotonin and norepinephrine. The converse is hypothesized for mania. Because antidepressants significantly increase the availability of those neurotransmitters, they can spark mania in some biologically vulnerable people.
So can ''recreational'' drugs like cocaine and methamphetamine, which instantly flood the brain with another neurotransmitter that regulates mood, dopamine.
The problem is that the milder types of bipolar disorder are often hard to recognize as an illness because the symptoms are chronic and less severe. In contrast, a person who develops a florid acute disease, whether appendicitis or full-scale mania, is obviously ill to any casual observer, because the contrast between the normal base line and the illness is stark.
Bruce, his family and friends, as well as his physicians were all taken in by his hypomania masquerading as mere happiness. In effect, they mistook his bipolar illness for his personality.
In the end, Bruce has responded very well to lamotrigine, an anticonvulsant mood stabilizer. Some time after, he was calm and rational and had an even mood. It was only then that he was able to see clearly the illness that nearly destroyed him. Now he is beginning to put the pieces of his life back together.Continue reading the main story
1. Dunner DL, Gershon ES, Goodwin FK. Heritable factors in the severity of affective illness. Biol Psychiatry. 1976;11:31–42.[PubMed]
2. Cassano GB, Dell’Osso L, Frank E, Miniati M, Fagiolini A, Shear K, et al. The bipolar spectrum: A clinical reality in search of diagnostic criteria and an assessment methodology. J Affect Disord. 1999;54:319–28.[PubMed]
3. Altshuler LL, Curran JG, Hauser P, Mintz J, Denicoff K, Post R. T2 hyperintensities in bipolar disorder: Magnetic resonance imaging comparison and literature meta-analysis. Am J Psychiatry. 1995;152:1139–44.[PubMed]
4. Kato T, Kunugi H, Nanko S, Kato N. Association of bipolar disorder with the 5178 polymorphism in mitochondrial DNA. Am J Med Genet. 2000;96:182–6.[PubMed]
5. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543–52.[PMC free article][PubMed]
6. Benazzi F. Bipolar II disorder: Epidemiology, diagnosis and management. CNS Drugs. 2007;21:727–40.[PubMed]
7. Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007;9:531–5.[PubMed]
8. Ghaemi SN, Sachs GS, Chiou AM, Pandurangi AK, Goodwin K. Is bipolar disorder still underdiagnosed? Are depressants overutilized? J Affect Disord. 1999;52:135–44.[PubMed]
9. Ghaemi SN, Ko JY, Goodwin FK. “Cade's disease” and beyond: Misdiagnosis, antidepressant use, and proposed definition for bipolar spectrum disorder. Can J Psychiatry. 2002;47:125–34.[PubMed]
10. MacQueen GM, Young LT. Bipolar II disorder: Symptoms, course, and response to treatment. Psychiatr Serv. 2001;52:358–61.[PubMed]
11. Piver A, Yatham LN, Lam RW. Bipolar spectrum disorders.New perspectives. Can Fam Physician. 2002;48:896–904.[PMC free article][PubMed]
12. Goodwin G. Hypomania: What's in a name? Br J Psychiatry. 2002;181:94–5.[PubMed]
13. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord. 1998;50:143–51.[PubMed]
14. Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rössler W. Toward a re-definition of subthreshold bipolarity: Epidemiology and proposed criteria for bipolar II, minor bipolar disorders and hypomania. J Affect Disord. 2003;73:133–46.[PubMed]
15. Benazzi F. Antidepressant-associated hypomania in outpatient depression: A 203-case study in private practice. J Affect Disord. 1997;46:73–7.[PubMed]
16. Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Keller M, et al. Switching from ‘unipolar’ to bipolar II: An 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry. 1995;52:114–23.[PubMed]
17. Benazzi F, Akiskal HS. Refining the evaluation of bipolar II: Beyond the strict SCID-CV guidelines for hypomania. J Affect Disord. 2003;73:33–8.[PubMed]
18. Simpson SG, McMahon FJ, McInnis MG, MacKinnon DF, Edwin D, Folstein SE, et al. Diagnostic reliability of bipolar II disorder. Arch Gen Psychitary. 2002;59:736–40.[PubMed]
19. Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE, Jr, et al. Development and validation of a screening instrument for bipolar spectrum disorder: The Mood Disorder Questionnaire. Am J Psychiatry. 2000;157:1872–5.[PubMed]
20. Angst J, Adolfsson R, Benazzi F, Gamma A, Hantouche E, Meyer TD, et al. The HCL-32: Towards a self-assessment tool for hypomanic symptoms in outpatients. J Affect Disord. 2005;88:217–33.[PubMed]
21. Tondo L, Baldessarini RJ, Hennen J, Floris G. Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders. Am J Psychiatry. 1998;155:638–45.[PubMed]
22. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: Re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003;73:121–31.[PubMed]
23. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA, et al. Psychosocial disability in the course of bipolar I and II disorders: A prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005;62:1322–30.[PubMed]
24. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261–9.[PubMed]
25. Vieta E, Suppes T. Bipolar II disorder: Arguments for and against a distinct diagnostic entity. Bipolar Disord. 2008;10:163–78.[PubMed]
26. Suppes T, Marangell LB, Bernstein IH, Kelly DI, Fischer EG, Zboyan HA, et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord. 2008;111:334–43.[PMC free article][PubMed]
27. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorder (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disord. 2009;11:225–55.[PubMed]
28. Grunze H, Kasper S, Goodwin G, Bowden C, Möller HJ. WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. Part III: Maintenance Treatment. World J Biol Psychiatry. 2004;5:120–35.[PubMed]
29. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht RW, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry. 2003;4:5–13.[PubMed]
30. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania. World J Biol Psychiatry. 2009;10:85–116.[PubMed]
31. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Association; 1994. American Psychiatric Association.
32. Royal Australian and New Zealand College of Psychiatrists. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry. 2004;38:280–305.[PubMed]
33. National Institute for Health and Clinical Excellence. NICE clinical guideline 38. Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. 2006 Jul
34. Rush AJ, Rago WV, Crismon ML, Toprac MG, Shon SP, Suppes T, et al. Medication treatment for the severely and persistently mentally ill: The Texas Medication Algorithm Project. J Clin Psychiatry. 1999;60:284–91.[PubMed]
35. Vieta E, Gastó C, Colom F, Reinares M, Martínez-Arán A, Benabarre A, et al. Role of risperidone in bipolar II: An open 6-month study. J Affect Disord. 2001;67:213–9.[PubMed]
36. Janenawasin S, Wang PW, Lembke A, Schumacher M, Das B, Santosa CM, et al. Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders. Bipolar Disord. 2002;4:328–34.[PubMed]
37. Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD, Banov M, et al. Olanzapine versus valproate versus placebo in the treatment of mild to moderate mania: A randomized, 12-week, double-blind study. J Clin Psychiatry. 2008;69:1776–89.[PubMed]
38. Basco MR, Rush AJ. New York: Guildford Press; 1996. Cognitive behavioral therapy for bipolar disorder.
39. Arvilommi P, Suominen KS, Mantere OK, Leppämäki S, Valtonen H, Isometsä ET. Adequacy of treatment received by diagnosed and undiagnosed patients with bipolar I and II disorders. J Clin Psychiatry. 2007;68:102–10.[PubMed]
40. Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv. 2007;58:85–91.[PubMed]
41. Calabrese JR, Keck PE, Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351–60.[PubMed]
42. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression.A Double-blind, Placebo-controlled Study (The BOLDER II Study) J Clin Psychopharmacol. 2006;26:600–9.[PubMed]
43. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I) J Clin Psychiatry. 2010;71:150–62.[PubMed]
44. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II) J Clin Psychiatry. 2010;71:163–74.[PubMed]
45. Suppes T, Hirschfeld RM, Vieta E, Raines S, Paulsson B. Quetiapine for the treatment of bipolar II depression: Analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry. 2008;9:198–211.[PubMed]
46. Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W. BOLDER Study Group. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: A randomized, double-blind, placebo controlled study. Bipolar Disord. 2007;9:413–25.[PubMed]
47. Hirschfeld RM, Weisler RH, Raines SR, Macfadden W. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: A secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67:355–62.[PubMed]
48. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzepine and olanzepine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60:1079–88.[PubMed]
49. Liebowitz MR, Salmán E, Mech A, Dunner D, Johnson AE, Akhtar J, et al. Ziprasidone monotherapy in bipolar II depression: An open trial. J Affect Disord. 2009;118:205–8.[PubMed]
50. Suppes T, Marangell LB, Fischer EG, et al. Acute treatment of bipolar II depression with monotherapy lithium versus lamotrigine: An open randomized trial of 102 patients. Bipolar Disord. 2007;9(Suppl 1):101.
51. Winsberg ME, DeGolia SG, Strong CM, Ketter TA. Valproate therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord. 2001;67:207–12.[PubMed]
52. Ketter TA, Wang PW, Nowakowska C, et al. Valproate-extended release monotherapy and adjunctive therapy in bipolar II depression. Bipolar Disord. 2007;9(Suppl 1):58.
53. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: A controversy revisited. Am J Psychiatry. 1995;152:1130–8.[PubMed]
54. Henry C, Sorbara F, Lacoste J, Gindre C, Leboyer M. Antidepressant-induced mania in bipolar patients: Identification of risk factors. J Clin Psychiatry. 2001;62:249–55.[PubMed]
55. Vieta E. Case for caution, case for action. Bipolar Disord. 2003;5:434–5.[PubMed]
56. Joffe RT, MacQueen GM, Marriott M, Robb J, Begin H, Young LT. Induction of mania and cycle acceleration in bipolar disorder: Effect of different classes of antidepressant. Acta Psychiatr Scand. 2002;105:427–30.[PubMed]
57. Altshuler LL, Suppes T, Black DO, Nolen WA, Leverich G, Keck PE, Jr, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry. 2006;163:313–5.[PubMed]
58. Amsterdam JD, Garcia-España F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol. 1998;18:435–40.[PubMed]
59. Amsterdam JD, Brunswick DJ. Antidepressant monotherapy for bipolar type II major depression. Bipolar Disord. 2003;5:388–95.